These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 27340117)

  • 1. Pemphigus Herpetiformis With Autoantibodies to Desmoglein 1 and 3.
    Galvañ-Pérez Del Pulgar JI; Tercedor-Sánchez J; Jiménez-Gallo D; Linares-Barrios M
    Actas Dermosifiliogr; 2016 Nov; 107(9):785-786. PubMed ID: 27340117
    [No Abstract]   [Full Text] [Related]  

  • 2. Case of pemphigus herpetiformis with immunoglobulin G autoantibodies against desmocollin-3.
    Ansai O; Shimomura Y; Fujimoto A; Sakai A; Tsuchida Y; Hayashi R; Shigehara Y; Hama N; Abe R
    J Dermatol; 2017 Jan; 44(1):104-105. PubMed ID: 27177601
    [No Abstract]   [Full Text] [Related]  

  • 3. Pruritic Blistering Eruption: Answer.
    Abbas A; Flowers RH; Noland MB; Gru AA
    Am J Dermatopathol; 2020 Feb; 42(2):144-145. PubMed ID: 31990703
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunoserological analyses of 55 patients with pemphigus at the Dermatological Department of Kurume University Hospital: an 11-year retrospective study (1996-2006).
    Ishii N; Maeyama Y; Karashima T; Nakama T; Kusuhara M; Yasumoto S; Hashimoto T
    Int J Dermatol; 2008 Dec; 47(12):1321-2. PubMed ID: 19126032
    [No Abstract]   [Full Text] [Related]  

  • 5. Herpetiform pemphigus without anti-desmoglein 1/3 autoantibodies.
    Nakashima H; Fujimoto M; Watanabe R; Ishiura N; Yamamoto AI; Hashimoto T; Tamaki K
    J Dermatol; 2010 Mar; 37(3):264-8. PubMed ID: 20507392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of pemphigus herpetiformis with absence of antibodies to desmogleins 1 and 3.
    Miura T; Kawakami Y; Oyama N; Ohtsuka M; Suzuki Y; Ohyama B; Hashimoto T; Motoki Y; Yamamoto T
    J Eur Acad Dermatol Venereol; 2010 Jan; 24(1):101-3. PubMed ID: 20050294
    [No Abstract]   [Full Text] [Related]  

  • 7. IgG/IgA pemphigus with IgG and IgA antidesmoglein 3 antibodies and IgA antidesmoglein 1 antibodies detected by enzyme-linked immunosorbent assay: a case report and review of the literature.
    Zaraa I; Kerkeni N; Sellami M; Chelly I; Zitouna M; Makni S; Mokni M; Ben Osman A
    Int J Dermatol; 2010 Mar; 49(3):298-302. PubMed ID: 20465668
    [No Abstract]   [Full Text] [Related]  

  • 8. IgA pemphigus--occurrence of anti-desmocollin 1 and anti-desmoglein 1 antibody reactivity in an individual patient.
    Kopp T; Sitaru C; Pieczkowski F; Schneeberger A; Födinger D; Zillikens D; Stingl G; Karlhofer FM
    J Dtsch Dermatol Ges; 2006 Dec; 4(12):1045-50. PubMed ID: 17176412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme-linked immunosorbent assay as a helpful diagnostic tool for pemphigus erythematosus with equivocal histologic and immunofluorescent findings.
    Desai A; Harris J; Motaparthi K
    Dermatol Online J; 2018 Aug; 24(8):. PubMed ID: 30677852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Desmoglein ELISA in the diagnosis of pemphigus and its correlation with the severity of pemphigus vulgaris.
    Mortazavi H; Shahdi M; Amirzargar AA; Naraghi ZS; Valikhani M; Daneshpazhooh M; Vasheghani-Farahani A; Sedaghat M; Chams-Davatchi C
    Iran J Allergy Asthma Immunol; 2009 Mar; 8(1):53-6. PubMed ID: 19279360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of desmoglein 1 and 3 enzyme-linked immunosorbent assay and direct immunofluorescence for evaluation of immunological remission in pemphigus vulgaris.
    Daneshpazhooh M; Kamyab K; Kalantari MS; Balighi K; Naraghi ZS; Shamohammadi S; Mortazavizadeh SM; Ramezani A; Chams-Davatchi C
    Clin Exp Dermatol; 2014 Jan; 39(1):41-7. PubMed ID: 23782219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Case no. 3. Bullous dermatosis].
    Battistella M
    Ann Pathol; 2013 Jun; 33(3):187-92. PubMed ID: 23790659
    [No Abstract]   [Full Text] [Related]  

  • 13. Case of bullous pemphigoid coexisting with anti-desmoglein autoantibodies.
    Tie D; Yoshida T; Chinuki Y; Da X; Ishikawa N; Morita E
    J Dermatol; 2017 Jul; 44(7):822-825. PubMed ID: 28342216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [D-penicillamine-induced pemphigus: changes in anti-32-2B immunostaining patterns].
    Khashoggi M; Machet L; Perrinaud A; Brive D; Machet MC; Maruani A; Vaillant L
    Ann Dermatol Venereol; 2013; 140(8-9):531-4. PubMed ID: 24034638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical pemphigus involving the esophagus with IgG antibodies to desmoglein 3 and IgA antibodies to desmoglein 1.
    Inui S; Amagai M; Tsutsui S; Fukuhara-Yoshida S; Itami S; Katayama I
    J Am Acad Dermatol; 2006 Aug; 55(2):354-5. PubMed ID: 16844530
    [No Abstract]   [Full Text] [Related]  

  • 16. Mixed bullous disease.
    Barranco VP
    Arch Dermatol; 1974 Aug; 110(2):221-4. PubMed ID: 4604780
    [No Abstract]   [Full Text] [Related]  

  • 17. Rituximab in pemphigus foliaceous with autoantibodies against both Desmoglein 1 and Desmoglein 3.
    Carvalho R; Maio P; Cunha D; Freitas I; Afonso A; Cardoso J
    Eur J Dermatol; 2011; 21(3):415-6. PubMed ID: 21527367
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of anti-desmoglein-1 and anti-desmoglein-3 autoantibody titers in pemphigus patients at the time of the initial diagnosis and after clinical remission.
    Russo I; De Siena FP; Saponeri A; Alaibac M
    Medicine (Baltimore); 2017 Nov; 96(46):e8801. PubMed ID: 29145342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desmoglein1 and BP 180 ELISA indexes correlating with disease activity in a patient with coexisting pemphigus foliaceus and bullous pemphigoid.
    Ando S; Sato-Matsumura KC; Kasai M; Nemoto-Hasebe I; Hoshina D; Ohyama B; Hashimoto T; Shimuzu H
    Clin Exp Dermatol; 2009 Dec; 34(8):e995-6. PubMed ID: 20055881
    [No Abstract]   [Full Text] [Related]  

  • 20. Correlation of IgG autoantibodies against acetylcholine receptors and desmogleins in patients with pemphigus treated with steroid sparing agents or rituximab.
    Bhatia SM; Streilein RD; Hall RP
    PLoS One; 2020; 15(6):e0233957. PubMed ID: 32555697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.